Ceribell, Inc. Reports 36% Revenue Growth and FDA Clearances for Fiscal Year 2025

**Ceribell, Inc. Reports Fiscal Year 2025 Financial Results and Strategic Developments**

Ceribell, Inc., a medical technology company specializing in neurological condition management, announced its financial results for the fiscal year ended December 31, 2025. The company reported total revenue of $89.1 million, a 36% increase compared to the $65.4 million reported for the fiscal year 2024. This revenue growth was attributed to a 34% increase in product revenue, reaching $67.3 million, and a 41% increase in subscription revenue, totaling $21.7 million. The company's growth was driven by the adoption of the Ceribell System by over 600 hospitals, ranging from top academic centers to small community hospitals.

Despite the revenue growth, Ceribell reported a net loss of $53.4 million for fiscal year 2025, compared to a net loss of $40.5 million in the previous fiscal year. The company's gross margin remained strong at 88%, slightly up from 87% in fiscal year 2024, with subscription gross margins consistently high at 97% for both years. Operating expenses increased significantly, with research and development expenses rising by 41% to $19.1 million, sales and marketing expenses increasing by 49% to $73.1 million, and general and administrative expenses increasing by 31% to $44.5 million. These increases were primarily due to headcount expansion, increased marketing efforts, and costs associated with operating as a public company.

Operationally, Ceribell achieved several milestones, including FDA 510(k) clearance for its delirium monitoring solution in December 2025, marking the first FDA-cleared device for delirium detection and monitoring. In January 2026, the company announced FDA Breakthrough Device Designation for its Large Vessel Occlusion (LVO) stroke detection and monitoring solution, currently in development. As of December 31, 2025, Ceribell had 327 full-time employees and a patent portfolio containing 58 total issued utility patents and pending utility patent applications.

Looking ahead, Ceribell aims to increase adoption of the Ceribell System in new and existing accounts, drive awareness of seizures and delirium in acute care settings, and continue to improve and innovate the Ceribell System. The company also plans to expand into new indications and clinical use cases beyond seizures and delirium, as well as pursue adjacent and international markets. The company believes that with its recently expanded indication for delirium, its annual addressable market opportunity has increased to over $3.5 billion.